Pancreatic Cancer Research

ResearcherCatholic University of KoreaActive in the last 2 years

Tae Ho Hong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3864-8104; OpenAlex author ID A5025882911, A5158010640. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 4 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 21

  1. Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
  2. Pretreatment Serum GDF-15 and Features of Clinical Vulnerability in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm15207789↗
  3. Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implicatio… Co-author DOI 10.3390/ijms262210908↗
  4. Establishment of an orthotopic nude mouse model for recurrent pancreatic cancer after complete resection: an experimental animal study. First author DOI 10.4174/astr.2025.108.5.317↗
  5. The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12040903↗
  6. The role of natural killer cell activity as a milestone in oncologic outcome after curative resection of pancreatic adenocarcinoma. Last author DOI 10.1002/jso.27432↗
  7. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer. Co-author DOI 10.1186/s12885-023-10811-8↗
  8. 15-Year Experience of Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer-A Korean Nationwide Investigation. Co-author DOI 10.3390/cancers15153850↗
  9. Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression. Co-author DOI 10.3390/jcm12165394↗
  10. Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer. First author DOI 10.3390/biomedicines10061289↗
  11. Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, r… First author DOI 10.1007/s00595-021-02280-y↗
  12. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observat… Co-author DOI 10.1186/s12885-020-07753-w↗
  13. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a r… Co-author DOI 10.1186/s12885-021-08887-1↗
  14. Benefits of the multiplanar and volumetric analyses of pancreatic cancer using computed tomography. Co-author DOI 10.1371/journal.pone.0240318↗
  15. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Last author DOI 10.4251/wjgo.v11.i11.1021↗
  16. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. Co-author DOI 10.1002/jcsm.12274↗
  17. Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III? Co-author DOI 10.1016/j.ejca.2018.08.027↗
  18. Initial experience with laparoscopic radical antegrade modular pancreatosplenectomy for left-sided pancreatic cancer in a single institution: technical aspects… First author DOI 10.1186/s12893-016-0200-z↗
  19. Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.3857/roj.2014.32.2.49↗
  20. MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens. Co-author DOI 10.4174/astr.2014.87.6.290↗
  21. Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. Co-author DOI 10.1007/s00432-012-1234-y↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Myung Ah Lee · 15 shared papers, 2012–2026 · strength 2.42
  2. Kabsoo Shin · 7 shared papers, 2019–2026 · strength 1.52
  3. Se Jun Park · 7 shared papers, 2019–2026 · strength 1.52
  4. In-Ho Kim · 4 shared papers, 2021–2025 · strength 0.84
  5. In Seok Lee · 6 shared papers, 2012–2022 · strength 0.66
  6. Moon Hyung Choi · 5 shared papers, 2018–2022 · strength 0.63
  7. Sung Eun Park · 1 shared paper, 2025 · strength 0.54
  8. Seung Bae Yoon · 4 shared papers, 2018–2022 · strength 0.46
  9. In Woong Han · 2 shared papers, 2023–2026 · strength 0.38
  10. Yoo‐Seok Yoon · 2 shared papers, 2023–2026 · strength 0.38
  11. Eun Sun Jung · 3 shared papers, 2018–2022 · strength 0.37
  12. Ja Hee Suh · 2 shared papers, 2021–2023 · strength 0.36
  13. Ji Hyun Lee · 1 shared paper, 2026 · strength 0.33
  14. Young Chul Yoon · 1 shared paper, 2023 · strength 0.31
  15. Eun Young Kim · 1 shared paper, 2023 · strength 0.31
  16. Meiying Song · 3 shared papers, 2018–2020 · strength 0.29
  17. Dongwoo Cho · 1 shared paper, 2025 · strength 0.26
  18. Ho Joong Choi · 2 shared papers, 2018–2022 · strength 0.25
  19. Julian Choi · 1 shared paper, 2026 · strength 0.19
  20. Jin-Young Jang · 1 shared paper, 2026 · strength 0.19
  21. Ju Won Kim · 1 shared paper, 2026 · strength 0.19
  22. Hye Jin Choi · 1 shared paper, 2026 · strength 0.19
  23. Keun Soo Ahn · 1 shared paper, 2026 · strength 0.19
  24. Hye‐Sol Jung · 1 shared paper, 2026 · strength 0.19
  25. Chang-Sup Lim · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.